Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that data from the landmark MINDACT study will be shared at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting in an oral presentation.
Agendia, Inc., a world leader in precision oncology for breast cancer, announced that new data from the first-of-its kind, national FLEX registry was debuted today at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
Oral presentation at ASCO 2021 highlights long term data with higher than 99% 8-year breast cancer specific survival for patients with MammaPrint Ultra Low Risk status regardless of clinical risk
(0)
Whole transcriptome analysis of ER+ breast cancers showed no substantial difference in gene expression between tumors from women younger than 50 and women older than 50
Whole transcriptome analysis confirms that genomic expression profiles from BluePrint ER+ Basal tumors and ER- Basal tumors are very similar, providing clinically actionable information to guide neoadjuvant treatment decisions
FLEX real-world registry to enroll 10,000 patients with breast cancer by end of 2021, with ultimate goal to enroll 30,000 total Agendia, Inc., a world leader in precision oncology for breast cancer, announced that new data from the first-of-its kind, national FLEX registry was debuted today at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
Agendia, Inc.: Landmark Long-Term Data from EORTC's MINDACT Study Published in The Lancet Oncology finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.